Literature DB >> 2687422

Discovery, development, and some uses of vasopressin and oxytocin antagonists.

M Manning1, W H Sawyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2687422

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


× No keyword cloud information.
  15 in total

1.  Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.

Authors:  A Giełdoń; R Kaźmierkiewicz; R Slusarz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

2.  Antidiuretic hormone acts via V1 receptors on intracellular calcium in the isolated perfused rabbit cortical thick ascending limb.

Authors:  R Nitschke; U Fröbe; R Greger
Journal:  Pflugers Arch       Date:  1991-02       Impact factor: 3.657

3.  Centrally released oxytocin mediates mating-induced anxiolysis in male rats.

Authors:  Martin Waldherr; Inga D Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-09       Impact factor: 11.205

4.  Anxiolytic effects of oxytocin in cue-induced cocaine seeking behavior in rats.

Authors:  Amarilys Morales-Rivera; Mayté M Hernández-Burgos; Arlene Martínez-Rivera; Jeremy Pérez-Colón; Raymond Rivera; Janitza Montalvo; Enrique Rodríguez-Borrero; Carmen S Maldonado-Vlaar
Journal:  Psychopharmacology (Berl)       Date:  2014-04-24       Impact factor: 4.530

5.  Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.

Authors:  A Ohnishi; Y Orita; R Okahara; H Fujihara; T Inoue; Y Yamamura; Y Yabuuchi; T Tanaka
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

6.  Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin.

Authors:  F A László; C Varga; T Dóczi
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

7.  Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.

Authors:  Y Yamamura; H Ogawa; H Yamashita; T Chihara; H Miyamoto; S Nakamura; T Onogawa; T Yamashita; T Hosokawa; T Mori
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

Review 8.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

9.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Authors:  C Serradeil-Le Gal; J Wagnon; C Garcia; C Lacour; P Guiraudou; B Christophe; G Villanova; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  Absorption of an oxytocin antagonist (antocin) and a vasopressin analogue (dDAVP) through a standardized skin erosion in volunteers.

Authors:  S Lundin; P Svedman; P Höglund; K Jönsson; A Broeders; P Melin
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.